The status and preparation for the next decade of biosimilars in the Middle Eastern and North African region
- 26 July 2023
- journal article
- research article
- Published by Taylor & Francis in Expert Opinion on Biological Therapy
- Vol. 23 (8) , 671-677
Abstract
Little is known about the status and the future potential of biosimilars in the Middle East and North Africa (MENA) region. This perspective provides insights into the current regulatory landscape of some MENA countries, currently available biosimilars, the potential of biosimilars in the next decade, and challenges to overcome. Given the economic and demographic heterogeneity across the MENA countries, biosimilars could reduce significant economic unmet needs in these countries. In the next decade, biosimilars may witness higher approval rates and market share over their originators in the MENA countries. We argue that the regulatory bodies in the MENA countries should adopt the new policies of the FDA, the EMA, and the WHO, that aim to ease the biosimilar approval process. These policies are to adopt technology in the process of approval; engage health technology assessment bodies in price assessment; provide educational materials to increase awareness among providers, patients, and payers. Further, MENA countries should upgrade the external-reference pricing systems to more sophisticated ones that consider the heterogeneity in economics and needs.Keywords
This publication has 15 references indexed in Scilit:
- Conversion to supportive care with biosimilar pegfilgrastim-cbqv enables budget-neutral expanded access to R-CHOP treatment in non-Hodgkin lymphomaLeukemia Research, 2021
- Cost-efficiency and expanded access of prophylaxis for chemotherapy-induced (febrile) neutropenia: economic simulation analysis for the US of conversion from reference pegfilgrastim to biosimilar pegfilgrastim-cbqvJournal of Medical Economics, 2020
- Pricing methods in outcome-based contracting: δ3: reference-based pricingJournal of Medical Economics, 2020
- Explaining biosimilars and how reverse engineering plays a critical role in their developmentExpert Opinion on Drug Discovery, 2020
- Economic modeling for the US of the cost-efficiency and associated expanded treatment access of conversion to biosimilar pegfilgrastim-bmez from reference pegfilgrastimJournal of Medical Economics, 2020
- Febrile neutropenia hospitalization due to pegfilgrastim on-body injector failure compared to single-injection pegfilgrastim and daily injections with reference and biosimilar filgrastim: US cost simulation for lung cancer and non-Hodgkin lymphomaJournal of Medical Economics, 2019
- Reply: Cost-efficiency analyses for the US of biosimilar filgrastim-sndz, reference filgrastim, pegfilgrastim, and pegfilgrastim with on-body injector in the prophylaxis of chemotherapy-induced (febrile) neutropeniaJournal of Medical Economics, 2018
- Expanded access to cancer treatments from conversion to neutropenia prophylaxis with biosimilar filgrastim-sndzFuture Oncology, 2017
- Cost-efficiency analyses for the US of biosimilar filgrastim-sndz, reference filgrastim, pegfilgrastim, and pegfilgrastim with on-body injector in the prophylaxis of chemotherapy-induced (febrile) neutropeniaJournal of Medical Economics, 2017
- Ten years of biosimilars in Europe: development and evolution of the regulatory pathwaysDrug Design, Development and Therapy, 2017